All In Biotech

Drug Trial Radar · NCT00369577

Staccato Loxapine in Agitation (Proof of Concept)

A Multi-center, Randomized, Double-blind, Placebo-controlled, Single Dose Efficacy and Safety Study of StaccatoTM Loxapine for Inhalation in Schizophrenic Patients With Agitation.

Last checked: Nov 20, 2026Latest source record: Jan 2, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 129 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

129

Actual

Start

Aug 2006

Primary completion

Jan 2007

Study completion Jan 2007

Sponsor

Lead sponsor
Alexza Pharmaceuticals, Inc.Not stated
Sponsor type
Not stated
First posted
Aug 29, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess efficacy and safety of Staccato Loxapine in the treatment of acute agitation in schizophrenic patients. The study will be conducted in 120 agitated schizophrenic patients - either newly admitted to a hospital setting or a research unit for acute agitation or already in hospital for chronic underlying conditions. Patients meeting entry criteria will be randomized to one of two doses of Staccato Loxapine or to Staccato Placebo. Following administration of study drug, assessment of agitation state will be conducted at serial time points using standard agitation scales over a 24 hour period.

Conditions

  • Schizophrenia

Interventions

  • Inhaled PlaceboDrug

    Inhaled Placebo, single dose

  • Inhaled Loxapine 5 mgDrug

    Inhaled Staccato Loxapine 5 mg, single dose

  • Inhaled Loxapine 10 mgDrug

    Inhaled Staccato Loxapine 10 mg, single dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PANSS-EC Change From BaselineTime frame: 2 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pacific Clinical Research Medical Group, 1317 West Foothill Blvd, Suite 200,

    Upland, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.